CytoReason

[Available On-Demand] ・ Click video to start playback; Join chat Q&A below video
Search General Info
CytoReason’s machine learning approach takes human clinical data and generates novel data-driven targets. This same approach is applied to drive drug development through indication prioritisation, combination identification and biomarker discovery. CytoReason’s access to unmatched proprietary and public data (the most extensive human clinical data in the field that includes retained clinical data from collaborators in our models) and cutting-edge machine learning technologies, combine to create our unique molecular-level biological models of disease, tissue and drug. Through these models we build a clear picture of what the cells, genes and proteins are doing in a disease, tissue and treatment environment, enabling us to uncover disease and drug mechanisms of action - and then turn that biology into valuable IP.
Company Type:
Company Website:
Company HQ State:
Not Provided
Company HQ Country:
Israel
Year Founded:
2016
Main Therapeutic Focus:
Lead Product in Development:
CytoPro/CytoKnow
Development Phase of Primary Product:
Number Of Unlicensed Products (For Which You Are Seeking Partners):
Not Applicable
Speaker
photo
Co-Founder and CEO
CytoReason